Gilead Wins FDA Approval for First Hepatitis Delta Drug

Gilead Sciences secured U.S. Food and Drug Administration (FDA) approval for bulevirtide, the first-ever treatment indicated for chronic hepatitis delta virus (HDV) infection, on 22 May 2026. The accelerated approval, reported by investing.com, covers adults with compensated liver disease. This decision creates a dedicated market for a serious liver condition affecting an estimated 15-20 million people globally, with a U.S. peak sales forecast of $1.2-1.8 billion. The drug will be marketed under the brand name Hepcludex, a name previously used for its European Union conditional authorization.

Context — why this matters now

Chronic hepatitis delta is the most severe form of viral hepatitis, accelerating liver fibrosis, cirrhosis, and hepatocellular carcinoma. The HDV virus requires hepatitis B surface antigen to replicate, co-infecting an estimated 5-10% of the 296 million people globally living with chronic hepatitis B. Until now, therapy has been limited to pegylated interferon-alpha, a treatment with significant side effects and low efficacy, achieving sustained virologic response in only 25-30% of patients after 48 weeks.

The macro backdrop features elevated valuations for rare disease and specialty drug developers following recent approvals in areas like non-alcoholic steatohepatitis (NASH). The Invesco Dynamic Pharmaceuticals ETF (PJP) gained 4.7% year-to-date through 21 May, underperforming the broader SPDR S&P Biotech ETF (XBI), which rose 8.1%. Regulatory innovation for unmet needs is a key performance driver.

The catalyst for the FDA decision was positive data from the Phase 3 MYR301 trial. That study demonstrated that 48 weeks of bulevirtide monotherapy resulted in combined virologic and biochemical response in 45% of patients, versus 2% for delayed treatment. The FDA had previously granted bulevirtide Breakthrough Therapy and Orphan Drug designations, streamlining its review pathway given the lack of alternative treatments for this progressive disease.

Data — what the numbers show

The addressable patient population for HDV is substantial, with an estimated 62,000 diagnosed patients in the United States and over 15 million worldwide. Gilead has not disclosed U.S. pricing, but analysts project an annual cost between $85,000 and $120,000. In the European Union, where the drug received conditional marketing authorization in July 2020, the annual list price is approximately €88,000 ($95,600).

A before-and-after comparison shows the magnitude of this development. Prior to this approval, the standard of care (pegylated interferon) cost roughly $40,000 annually with a 30% response rate. The new therapy is projected to cost over twice as much but targets a response rate nearly 50% higher, creating a significant net price premium for improved efficacy.

Gilead's overall antiviral portfolio, which includes HIV blockbusters Biktarvy and Descovy and hepatitis C drugs, generated $16.3 billion in revenue in fiscal 2025. The HDV asset is expected to contribute meaningfully within 3-5 years. For context, the total addressable market for the HDV segment is forecast to reach $2.6 billion globally by 2030, according to GlobalData analytics.

Peer comparisons highlight Gilead's dominance in virology. Merck's hepatitis B drug, Vemlidy, posted $887 million in 2025 sales. Vertex Pharmaceuticals, which has no HDV program, focuses on cystic fibrosis and saw its Trikafta franchise generate over $9 billion last year. Gilead shares (GILD) closed at $78.42 on 21 May, giving the company a market capitalization of $97.8 billion.

Analysis — what it means for markets / sectors / tickers

The immediate beneficiary is Gilead Sciences (GILD). Consensus analyst estimates suggest the HDV approval could add $800 million to $1.2 billion in annual revenue by 2028, representing a 4-6% uplift to total company sales. This strengthens Gilead's virology franchise beyond HIV, potentially supporting a valuation re-rating. Shares of smaller biotechs with HDV programs, like Eiger BioPharmaceuticals (EIGR), may see increased speculative interest as M&A targets.

Secondary beneficiaries include diagnostics firms. Quest Diagnostics (DGX) and Laboratory Corporation of America (LH) stand to gain volume from increased HDV screening recommendations for all hepatitis B patients, a guideline likely to be reinforced by the new treatment's availability. Increased monitoring for liver function and fibrosis in treated patients also supports volumes for these labs.

A key risk is the drug's safety profile and the conditional nature of its approval. The FDA mandated a post-marketing study to verify and describe the drug's clinical benefit. The most common adverse events in trials were injection-site reactions and elevated bile acids. Patient adherence to a daily subcutaneous injection could limit real-world uptake and effectiveness compared to trial results.

Positioning data from the options market shows increased call buying in GILD ahead of the decision. Flow has also moved into the iShares Nasdaq Biotechnology ETF (IBB), with net inflows of $142 million over the past week. Short interest in GILD remains low at 1.8% of float, indicating limited bearish conviction against the established large-cap name.

Outlook — what to watch next

The next major catalyst is the European Medicines Agency's decision on converting bulevirtide's conditional marketing authorization to full approval, expected in Q4 2026. A positive outcome would secure long-term EU market access and support pricing negotiations with national health authorities. The second catalyst is the release of 96-week durability data from the MYR301 study, slated for presentation at the European Association for the Study of the Liver (EASL) congress in November 2026.

Levels to watch for GILD share price include the 200-day moving average at $76.50, which now acts as technical support. Resistance sits near the $82 level, a high last tested in January 2026. A sustained breakout above $82 on elevated volume would signal strong institutional endorsement of the product's commercial potential. The 10-year Treasury yield, currently at 4.31%, remains a macro headwind for long-duration biotech assets if it rises further.

Investor focus will shift to early prescription trends tracked by IQVIA, with the first data expected 90 days post-launch. Commentary on the Q2 2026 earnings call regarding gross-to-net pricing discounts and payer reimbursement will be critical for calibrating revenue models. The performance of other late-stage liver disease assets in Gilead's pipeline, like its NASH candidate, will also influence sentiment.